Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25548946 | 0.98 | NQO1 (0.64) | NQO1TSHRTDP1ALDH1A1LTA4H | |
| SCHEMBL10613369 | 0.94 | NQO1 (0.58) | NQO1TSHRTDP1ALDH1A1LTA4H | |
| SCHEMBL17614864 | 0.94 | NQO1 (0.58) | NQO1TSHRTDP1ALDH1A1LTA4H | |
| SCHEMBL9664462 | 0.92 | NQO1 (0.56) | NQO1TSHRTDP1ALDH1A1LTA4H | |
| SCHEMBL8753212 | 0.90 | ACACB (0.60) | NQO1ACACB | |
| SCHEMBL27863856 | 0.88 | NQO1 (0.52) | NQO1TSHRTDP1ALDH1A1LTA4H | |
| SCHEMBL22222380 | 0.87 | ACACB (0.54) | NQO1ACACB | |
| SCHEMBL8986268 | 0.86 | NQO1 (0.61) | NQO1TSHRTDP1ALDH1A1MAPT | |
| SCHEMBL4248652 | 0.86 | NQO1 (0.67) | NQO1TSHRTDP1ALDH1A1LTA4H | |
| SCHEMBL12251519 | 0.85 | MAPT (0.66) | NQO1ALDH1A1MAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | INVIVOGEN (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-4188589-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2023-06-07 | — | — | EP | disclosed |
| CN-115515796-A | Thermosensitive recording medium | 王子控股株式会社 | 2022-12-23 | — | — | CN | disclosed |
| US-20210353760-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2021-11-18 | — | — | US | disclosed |
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2021-10-21 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| US-20180036286-A1 | BIS-CYCLIC GUANIDINE COMPOUND COMPOSITIONS, METHODS OF USE AND TREATMENT THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2018-02-08 | — | — | US | disclosed |
| US-20180036286-A1 | BIS-CYCLIC GUANIDINE COMPOUND COMPOSITIONS, METHODS OF USE AND TREATMENT THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2018-02-08 | — | — | US | disclosed |
| EP-3045466-B1 | (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL PROPYLENE GLYCOL SOLVATE AS SGT2 INHIBITOR FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| WO-2008024922-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | WYETH (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | BROWN ALAN D | 2007-11-15 | — | — | US | disclosed |
| CN-101071281-A | Toner | RICOH KK (JP) | 2007-11-14 | — | — | CN | disclosed |
| US-20070224538-A1 | Positive Resist Compositions and Process for the Formation of Resist Patterns With the Same | TOKYO OHKA KOGYO CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070224538-A1 | Positive Resist Compositions and Process for the Formation of Resist Patterns With the Same | TOKYO OHKA KOGYO CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2001044151-A1 | PREPARATION OF 2-(4-ETHOXYPHENYL)-2-METHYLPROPYL ALCOHOL | ISAGRO (ASIA) AGROCHEMICALS PRIVATE LIMITED (IN) | 2001-06-21 | — | — | WO | disclosed |
| EP-0057740-A1 | Pressure sensitive recording sheets | DIAMOND SHAMROCK CORPORATION (US) | 1982-08-18 | — | — | EP | disclosed |
| US-4229512-A | Toners for color flash fusers containing a permanent colorant and a heat sensitive dye | LENHARD MYRON J | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | STING1, CGAS, TLR9 | NQO1 854/4885TSHR 3488/4885TDP1 1701/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | NQO1 36/4885TSHR 3747/4885TDP1 226/4885 |
| US-20210353760-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | NQO1 854/4885TSHR 3488/4885TDP1 1701/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | NQO1 36/4885TSHR 3747/4885TDP1 226/4885 |
| US-20180036286-A1 | BIS-CYCLIC GUANIDINE COMPOUND COMPOSITIONS, METHODS OF USE AND TREATMENT THEREOF | GMPS, CGAS, RNMT | NQO1 1759/4885TSHR 4606/4885TDP1 258/4885 |
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | SLC5A1, SLC5A2, DPP4 | NQO1 757/4885TSHR 3697/4885TDP1 3205/4885 |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | ADRB2, ADRB1, ADRA2C | NQO1 1723/4885TSHR 1269/4885TDP1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.